UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest event Reported): January 4, 2017
CHINA BIOLOGIC PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 001-34566 | 75-2308816 |
(State or Other Jurisdiction of Incorporation or Organization) |
(Commission File No.) | (I.R.S. Employer Identification Number) |
18th Floor,
Jialong International Building
19 Chaoyang Park Road
Chaoyang District, Beijing 100125
People’s Republic of China
(Address of Principal Executive Offices)
86-10-6598-3166
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12) |
¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b)) |
¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
ITEM 7.01 REGULATION FD DISCLOSURE.
On January 4, 2017, China Biologic Products, Inc. (the “Company”) announced that the Company will participate in the 35th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel, San Francisco, California, January 9-12, 2017. Mr. David Gao, Chairman and Chief Executive Officer, Mr. Ming Yang, Chief Financial Officer, and Mr. Ming Yin, Senior Vice President of the Company, will meet with investors at the event. A copy of the press release is attached as Exhibit 99.1 to this current report and is incorporated herein by reference.
The materials that the Company’s management plans to use at the conference are available on the Company’s website, www.chinabiologic.com, and are being furnished as Exhibit 99.2 to this current report.
The information contained in this report, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
Safe Harbor Statements
Certain statements contained in the materials furnished with this current report contain forward-looking statements, including statements about the business outlook, strategy and market opportunity of the Company, and statements that may suggest trends for its business. Such forward-looking statements can be identified by the use of forward-looking terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would,” and similar expressions, or the negatives thereof. These statements are individually and collectively forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These forward-looking statements are made only as of the date of the materials and are based on estimates and information available to the Company at the time of the materials. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company’s control. Therefore, the Company cautions that actual results may differ materially from those set forth in any forward-looking statements herein as a result of a variety of factors, including, without limitation potential delay or failure to complete the clinical trials for new products, potential delay or failure to complete construction of new collection facilities, potential inability to pass government inspection and certification process for new collection facilities, potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company’s periodic reports that are filed with the SEC and available on its website (http://www.sec.gov). In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in the materials will in fact be realized. Any forward-looking statements and projections made by others in the materials are not adopted by the Company and the Company is not responsible for the forward-looking statements and projections of others. Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit Number |
Description | |
99.1 | Press release issued by the Company dated January 4, 2017 | |
99.2 | China Biologic Products, Inc. Conference Materials (January 2017) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CHINA BIOLOGIC PRODUCTS, INC. | |||||
Date: | January 4, 2017 | By: | /s/ David (Xiaoying) Gao | ||
Name: | David (Xiaoying) Gao | ||||
Title: | Chief Executive Officer |
Exhibit 99.1
China Biologic to Attend the 35th Annual J.P. Morgan Healthcare Conference
—Reiterates Full Year 2016 Financial Forecast—
BEIJING, China – January 4, 2017 – China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company will participate in the 35th Annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis Hotel, San Francisco, California, January 9-12, 2017. Mr. David Gao, Chairman and Chief Executive Officer, Mr. Ming Yang, Chief Financial Officer, and Mr. Ming Yin, Senior Vice President of China Biologic, will meet with investors at the event.
The Company reiterates its full year forecast of total sales growth of 22% to 24% in RMB terms and non-GAAP adjusted net income growth of 33% to 35% in RMB terms over the Company’s 2015 financial results. Non-GAAP adjusted net income excludes non-cash compensation expenses related to options and restricted shares granted to employees and directors. This guidance does not factor in any potential foreign currency translation impact. Having previously adopted an exchange rate of approximately RMB6.21 = $1.00 based on weighted average quarterly exchange rates in 2015 in translating 2015 financial results, the Company expects that the total sales and non-GAAP adjusted net income in USD terms in 2016 will be adversely affected by the foreign currency translation impact.
For additional information or interest in meeting with management, please contact your J.P. Morgan institutional sales representative.
About China Biologic Products, Inc.
China Biologic Products, Inc. (NASDAQ: CBPO), is a leading fully integrated plasma-based biopharmaceutical company in China. The Company’s products are used as critical therapies during medical emergencies and for the prevention and treatment of life-threatening diseases and immune-deficiency related diseases. China Biologic is headquartered in Beijing and manufactures over 20 different dosages of plasma-based products through its majority owned subsidiary, Shandong Taibang Biological Products Co., Ltd., and its wholly owned subsidiary, Guizhou Taibang Biological Products Co., Ltd. The Company also has an equity investment in Xi'an Huitian Blood Products Co., Ltd. The Company sells its products to hospitals, distributors and other healthcare facilities in China. For additional information, please see the Company's website www.chinabiologic.com.
Page 1 |
Non-GAAP Disclosure
This news release contains a non-GAAP financial measure, adjusted net income, that excludes from net income non-cash compensation expenses related to options and restricted shares granted to employees and directors under the Company’s 2008 Equity Incentive Plan. The Company’s management believes that this non-GAAP measure provides investors with a better understanding of the Company’s performance. This non-GAAP information is not meant to be considered in isolation or as a substitute for GAAP financials. The non-GAAP financial information that the Company provides also may differ from the non-GAAP information provided by other companies. A reconciliation of GAAP net income and non-GAAP adjusted net income for the full year 2016 will be provided when the Company announces its complete financial results for the fourth quarter and full year ended December 31, 2016 in February 2017.
In addition, as the Company evaluates certain key items of its financial results on a local currency basis (i.e., in RMB) in addition to the reporting currency (i.e., in USD), this news release contains local currency information that eliminates the impact of fluctuations in foreign currency exchange rates. The Company believes that, given its operations primarily based in China, providing local currency information on such key items enhances the understanding of its financial results and evaluation of performance in comparison to prior periods. Changes in local currency percentages are calculated by comparing financial results denominated in RMB from period to period.
Safe Harbor Statement
This news release may contain certain “forward-looking statements” relating to the business of China Biologic Products, Inc. and its subsidiaries. All statements, other than statements of historical fact included herein, are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “intend,” “believe,” “expect,” “are expected to,” “will,” or similar expressions, and involve known and unknown risks and uncertainties. Among other things, the forecast of total sales growth and non-GAAP adjusted net income growth contains forward-looking statements. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect.
Page 2 |
Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this news release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including, without limitation potential delay or failure to complete the clinical trials for new products, potential delay or failure to complete construction of new collection facilities, potential inability to pass government inspection and certification process for new collection facilities, potential inability to achieve the designed collection capacities at the new collection facilities, potential inability to achieve the expected operating and financial performance, potential inability to find alternative sources of plasma, potential inability to increase production at permitted sites, potential inability to mitigate the financial consequences of a temporarily reduced raw plasma supply through cost cutting or other efficiencies, and potential additional regulatory restrictions on its operations and those additional risks and uncertainties discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
Contact:
China Biologic Products, Inc.
Mr. Ming Yin
Senior Vice President
Phone: +86-10-6598-3099
Email: ir@chinabiologic.com
ICR Inc.
Mr. Bill Zima
Phone: 1-203-682-8233
E-mail: bill.zima@icrinc.com
Page 3 |
Exhibit 99.2
China Biologic Products, Inc. (NASDAQ: CBPO) 35 th Annual J.P . Morgan Healthcare Conference January 2017 Creating Miracles in Life
Safe Harbor Statement This presentation contains forward - looking statements, including statements about the business outlook, strategy and market opportunity of China Biologic Products, Inc . (the “Company” or “we”), and statements that may suggest trends for its business . Such forward - looking statements can be identified by the use of forward - looking terminology such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “should,” “will,” “would,” and similar expressions, or the negatives thereof . These statements are individually and collectively forward - looking statements within the meaning of Section 27 A of the Securities Act and Section 21 E of the Securities Exchange Act of 1934 . These forward - looking statements are made only as of the date of this presentation and are based on estimates and information available to the Company at the time of this presentation . These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict and may be beyond the Company’s control . Therefore, the Company cautions that actual results may differ materially from those set forth in any forward - looking statements herein, and are subject to numerous assumptions, risks, uncertainties and other factors, including those discussed under “Risk Factors” in the Company’s annual report on Form 10 - K filed with the SEC for the year ended December 31 , 2015 . In light of these risks and uncertainties, there can be no assurance that the forward - looking statements made during this presentation will in fact be realized . Any forward - looking statements and projections made by others in this presentation are not adopted by the Company and the Company is not responsible for the forward - looking statements and projections of others . Except as otherwise required by applicable securities laws, the Company disclaims any intention or obligation to publicly update or revise forward - looking statements, whether as a result of new information, future events or otherwise . In evaluating our business, we use certain non - GAAP measures as supplemental measures to review and assess our operating performance . These non - GAAP financial measures have limitations as analytical tools and investors should not consider them in isolation, or as a substitute for net income attributable to Company or other consolidated statement of comprehensive income data prepared in accordance with U . S . GAAP . China Biologic Products, Inc. 01
Capital Structure Price: $109.30 (12/28/2016) Market Capitalization: $3.0 billion 52 - Week Range: $100.53 - $144.29 Shares Outstanding : 27.1 mm Selected 9M16 Financials Revenue : $263.5 mm, up 15.5% in USD terms or 23.1% in RMB terms (2) y - o - y Gross Profit: $170.3 mm, up 14.5% y - o - y; Gross Margin: 64.6% Operating Income: $120.7 mm, up 9.7% y - o - y; Operating Margin: 45.7% Net Income: $85.3 mm, up 17.2% y - o - y; Non - GAAP Net Income (3) : $99.93 mm, up 25.3% in USD terms or 33.7% in RMB terms y - o - y Fully diluted EPS: $3.05; Non - GAAP EPS (3) : $3.57 Business Overview A fully integrated plasma - based biopharmaceutical company in China 8 categories of plasma - based products Headquartered in Beijing, with 3 production facilities (1 wholly owned (1) ; 1 majority owned; and 1 minority owned ) Founded in 2002 and listed on NASDAQ in 2009 (Ticker: CBPO) Market Position One of top three domestic suppliers in China for the two principal plasma products One of the first plasma companies in China to penetrate into end - user market, directly serving approximately 600 hospitals and clinics CBPO: A Leading Plasma Company in China China Biologic Products, Inc. 02 1 . We acquired the full equity ownership in Guizhou Taibang through capital withdrawal by its former minority stockholders in November 2016 . 2 . We believe providing local currency information on certain key items of our financial results enhances the understanding of our financial results and evaluation of performance in comparison to prior periods . We calculate changes in local currency percentages by comparing financial results denominated in RMB from period to period . 3 . Refer to Appendix I for reconciliation of Non - GAAP net income attributable to equity holders
CBPO 19% (1) CNBG Other Competitors Hepatitis Rabies Tetanus etc. FVIII PCC Fibrinogen etc. Fractionation lmmuno - globulins Hyper - Immuno - g lobulins Clotting f actors A lbumin Maintain osmotic pressure, etc. Infections , immune deficiencies (IVIG) CBPO Plasma Product Overview 03 Red cells ( 9M16 Sales % ) CBPO Sales Breakdown by Product Albumin 38.9% IVIG 35.5% Hyper - immune Products 11.6% P. Polypepti de 9.4% Others 4.6% CBPO 6% (1) CNBG Shanghai RAAS Foreign Player A Foreign Player B Foreign Player C Foreign Player D Foreign Player E Others (Based on 2015 Sales) 3rd Largest Domestic Player in China Albumin Market Largest Player in China IVIG M arket ( Based on 2015 Sales) Source: Company estimates based on the public release of government batch approval data. 1. Includes sales attributable to Xi’an Huitian , in which we hold a 35% non - controlling interest. F oreign players 90% Water 7% Proteins 3% Salt Blood White cells Platelets Plasma P.Polypeptide 9.4%
Industry Overview China Biologic Products, Inc. China Biologic Products, Inc.
Per Capita Usage in U.S. / Per Capita Usage in China (x ) 2014 Market Size in China ($ MM) ( By 2015 Product Sales ) 2014 Plasma Products Per Capita Usage Plasma Products (1) Structure Comparison In China, albumin is the largest product in plasma products market. In U.S., IVIG is the largest product, and various coagulation factor products are growing fast. China’s 2014 market size is $2.5 billion, but its per capita penetration is still a fraction of that of the U.S. 1,560 557 45 2.5x 15.8x 15.9x 0.0 5.0 10.0 15.0 20.0 Albumin IVIG Factor VIII (2) (2) (3) China’s Plasma Protein Market – Early Stage of Growth, Low Penetration, Significant Potential 05 0.8 2.5 6.2 0.0 2.0 4.0 6.0 8.0 2009 2014 2019E China Plasma Products (1) Market Size ($ Billion) CAGR 20% CAGR 26% Source: The Marketing Research Bureau, Inc. and Company estimates 1. Excluding recombinant products 2. Based on 2014 per capita usage (kilogram per MM inhabitant) in U.S. divided by 2014 per capita usage in China 3. Based on 2014 per capita usage (international units per capita) in U.S. divided by 2014 per capita usage in China , excluding recombinant products China is the second largest plasma products market in the world Significant unmet clinical demand provides sustainable growth Growth potential driven by aging population and various diseases Seller’s m arket with sustainable pricing Albumin 66.5% IVIG 24.4% Hyper - immune 6.1% FVIII 1.5% Others 1.5% Albumin and plasma protein fraction 7.0% IVIG&SCIG 57.2% FVIII 2.5% Alpha - 1 Antitrypsin 8.1% C - 1 Esterase Inhibitor 8.2% Others 17.0% China U.S.
Regulatory framework in China has evolved into one of the most stringent globally due to crises of tainted plasma products over the past decade Fractionators permitted to process self - collected plasma only as required by law New plasma collection licenses are difficult to obtain Plasma fractionation licenses ceased to be granted since 2001 ; 28 active plasma product manufacturers in China currently Since 1986 , all imported blood products have been banned except for human albumin and recombinant factor VIII products China will continue to maintain stringent regulations for the plasma product industry as it is critical to China's public health security High Barriers to Entry Benefit Established Players 06 China Biologic Products, Inc.
United States China Population (million) 319 1,375 Donation Frequency Twice per 7 days, not within 48 hours Twice per month, not within 14 days Collection Volume Volumes by weight 50 - 68kg / 69 - 79kg / >79kg, donate 690 / 825 / 880 ml 580 ml Plasma Collection Centers Over 480 Approximately 200 Preapproval Requirement No Yes Plasma Donation Compensation (for one time donation) $25 - 35 $42 - 50 Regulation Agencies Food and Drug Administration (FDA) and Plasma Protein Therapeutics Association (PPTA) County - , Municipal - and Provincial - Level Governments Plasma Collected in 2015 (million liters) 31.0 5.8 Source: Broker Report, The Marketing Research Bureau, Inc., Plasma Protein Therapeutics Association (PPTA) and Company estima tes Plasma Collection Regulation Environment – U.S. vs. China China Biologic Products, Inc. 07
Plasma Companies Other Pharma Companies Commentary Regulatory Control China’s plasma - derived products market is highly regulated by the government Supply / Demand Significant supply shortage favors leading plasma players Historical Pricing Prices for most plasma products have remained steady whereas the average price of many pharma products has been in decline Domestic Competition 28 active plasma product manufacturers in China vs. thousands of pharmaceutical companies Foreign Competition Currently only albumin and recombinant factor VIII are open to imports Sales and Distribution Compared with pharmaceutical companies, the plasma industry in China is a seller’s market Growth Visibility Growth among plasma manufacturers is primarily driven by the supply/demand imbalance Plasma Is An Attractive Sector For Investment In China Pharmaceutical Industry China Biologic Products, Inc. 08
404 1,560 3,420 0 1,000 2,000 3,000 4,000 2009 2014 2019E 197.2 500.8 0 100 200 300 400 500 600 China United States China is the world’s largest albumin market, but per capita usage is still lower than U.S. Consistent price increases since 2006. Price ceiling has been removed since June 1, 2015 Growth in disease prevalence and patient pool, such as hypoalbuminemia from liver cirrhosis and hepatitis B Plasma collection volume continues to grow ($ MM) (Kg per MM Inhabitants) Albumin Sales in China Albumin Per Capita Usage in 2014 CAGR 17% CAGR 31% Source: The Marketing Research Bureau, Inc. and Company estimates Albumin is used for treatment of shock caused by blood loss trauma or burn, raised intracranial pressure caused by hydrocepha lus or trauma, edema or ascites caused by hepatocirrhosis and nephropathy, prevention and treatment of low - density - lipoproteinemia and Neonatal hyperbilirubinemia. It is included in provincial essential drug lists of certain provinces and categorized as Class B i n China’s National Drug Reimbursement List Albumin: Largest Market with Growth Potential China Biologic Products, Inc. 09
IVIG Sales in China IVIG Per Capita Usage in 2014 12.7 200.4 0 50 100 150 200 250 China United States 254 557 1,569 0 300 600 900 1,200 1,500 1,800 2009 2014 2019E ($ MM) (Kg per MM Inhabitants) CAGR 23% CAGR 13% Source: The Marketing Research Bureau, Inc. and Company estimates IVIG is used for treatment of hereditary immunoglobulin deficiency, such as X chain low immunoglobulin, familial variable imm une deficiency, immunoglobulin G secondary deficiency; secondary immunoglobulin deficiency, such as severe infection, newborn sepsis; and auto - immune deficiency diseases, such as original thrombocytopenia purpura or Kawasaki disease. It is included in provincial essential drug lists and categorized as Class B in China’s National Drug Reimbursement List IVIG: Early - stage Market with Strong Growth Drivers China Biologic Products, Inc. 10 Largest product category globally yet still at an early - stage in China Growth of IVIG market will be driven by expanded indications and physician education Per Capita usage in China is less than 10% of that in U.S. IVIG’s pricing in China is currently less than half of that of the US, providing strong upside potential
Source: The Marketing Research Bureau, Inc. and Company estimates 1 . As of December 31, 2014, according to China Hemophilia Association 2. Excluding recombinant products Factor VIII is used for treatment of coagulopathie such as hemophilia A and increase concentration of coagulation factor VIII . I t is included in national essential drug lists and categorized as Class A in China’s National Drug Reimbursement List Factor VIII: Nascent Market, Strong Growth Potential and Highly Profitable China Biologic Products, Inc. 11 Factor VIII is a life saving and a lifelong treatment Room for significant growth for Factor VIII products in China ‒ Only 8 domestic manufacturers in the plasma - derived Factor VIII segment ‒ Over 10,000 (1) registered hemophilia patients in China, many more unregistered ‒ Primarily acute usage vs. little preventive usage, providing huge room for growth Recombinant Factor VIII is not competitive due to higher cost and lack of insurance coverage 0.12 1.91 0.0 0.4 0.8 1.2 1.6 2.0 2.4 China United States 11 45 85 0 20 40 60 80 100 2009 2014 2019E ($ MM) (International Units per Inhabitant) Factor VIII (2) Sales in China Factor VIII (2) Per Capita Usage in 2014 CAGR 14% CAGR 33%
Company Overview China Biologic Products, Inc.
Strong Product Pipeline Enhancing Margins and Leadership 4 Stable and Growing Plasma Supply 2 Robust Cash Flow and Sustainable Profitability 5 Leading Plasma Player in China 1 Leader in China’s Fast Growing IVIG Market 3 Professional and Experienced Management Team 6 The Only Offshore Investment Opportunity in the Attractive Chinese Plasma Industry 13 China Biologic Products, Inc.
38.5 71.1 74.3 93.5 109.4 72.3 87.3 57.0 74.5 86.9 116.2 132.6 110.0 120.7 37.2% 40.3% 42.7% 47.8% 44.7% 48.2% 45.7% -8.0% 2.0% 12.0% 22.0% 32.0% 42.0% 52.0% 0 50 100 150 200 2011 2012 2013 2014 2015 9M'15 9M'16 Operating Cash Flow Operating income Operating Margin Unique distribution model, products sold directly to ~600 hospitals and clinics Non - GAAP Net Income Attributable to Equity Holders ( 1) ($ MM) 153.1 184.8 203.4 243.3 296.5 228.2 263.5 0 60 120 180 240 300 360 420 2011 2012 2013 2014 2015 2016E 9M'15 9M'16 36.5 48 59 75.6 100.1 79.7 99.9 -20 10 40 70 100 130 2011 2012 2013 2014 2015 2016E 9M'15 9M'16 ($ MM) 1 Leading Plasma Company in China - Solid Track Record of Delivering Sustainable Profitability 14 Total Sales China Biologic Products, Inc. 1. Non - GAAP net income attributable to equity holders excludes non - cash employee stock compensation and some non - recurring items. Recurring operating income excludes non - recurring items. Refer to Appendix I for reconciliations. Operating Cash flow and Recurring Operating Income and Margin (1) ($ MM) The largest domestic plasma player in China in terms of 2015 total sales * * source : MRB report * Subject to foreign exchange translation impact
Product portfolio consisting of eight plasma products with strong economics High product quality and safety record Large scale and reliable product supply to hospitals Government support for leading players Advantages from Leading Market Position 1 Leading Plasma Player in China 15 China Biologic Products, Inc.
Extensive plasma collection network of 14 captive plasma stations (including 1 branch station) With recently opened Xinglong plasma station, plasma collection network now covers four provinces with a total combined population of 220 MM Continue to explore new regions to expand plasma donor coverage Daming collection station in Hebei Province is expected to commence operation in 2017 D rive plasma collection growth volume at our existing stations Secured additional 500 tonnes of source plasma from August 2015 to 2018 through strategic collaboration with a third party fractionator Cao County Plasma Collection Center, Shandong Puding Plasma Collection Center, Guizhou Strong plasma supply growth: annual plasma collection 2012 to 2015 CAGR CBPO: 15% V.S. China Average: 11 %* * Source: data published by National Health and Family Planning Commission of the PRC. 2 Growing and Sustainable Plasma Supply 16 China Biologic Products, Inc.
3 Leader in China’s Fast Growing IVIG Market 1 7 China Biologic Products, Inc. CBPO 19% (1) (1st) CNBG (2nd) Other Competitors 49 125 0 40 80 120 2011 2015 IVIG Sales 32.3% ($ MM) 42.2% % of Total Sales (based on 2015 Sales) CBPO’s Increasing S ales in IVIG Leading Player in China’s IVIG Market Source: : The Marketing Research Bureau, Inc., and Company estimates 1. Includes sales attributable to Xi’an Huitian , in which we hold a 35% non - controlling stak e 200.4 12.7 0 200 United States China 2014 (Kg per MM Inhabitants) China’s IVIG Market Has Substantial Growth Potential Enhancing Physician Education Expanding Therapeutic Indication Improving Insurance Reimbursement Low per capita Consumption of IVIG in China Sustainable Growth Drivers
Products Preclinical Research Clinical Trial Application Clinical Trial Commercial Launch Development Status Human Fibrinogen Commercial production expected in 2017 New Generation IVIG Obtained the approval for clinical trial by CFDA Human Antithrombin III Obtained the approval for clinical trial by CFDA Human Cytomegalovirus Immunoglobulin Obtained the approval for clinical trial by CFDA Human coagulation factor IX Obtained the approval for clinical trial by CFDA Human Fibrin Sealant Completed the official virus inactivation by the PRC National Institutes for Food and Drug Control 4 Robust and Low Risk Product Pipeline Enhancing Margins and Leadership 18 China Biologic Products, Inc. China Biologic Products, Inc.
Cost Albumin Immunoglobulin Factor VIII PCC Other Products Total Fractionation Revenue Profit Hyper - Immune Products IVIG Indicative Revenue and Profit Breakdown per Liter of Plasma Each new product will incrementally improve profit 4 Robust and Low Risk Product Pipeline Enhancing Margins and Leadership (continued) 19 China Biologic Products, Inc.
38.5 71.1 74.3 93.5 109.4 72.3 87.3 0 25 50 75 100 125 2011 2012 2013 2014 2015 9M'15 9M'16 5 Robust Cash Flow Generation 20 China Biologic Products, Inc. ($ MM) Operating Cash Flow 8.0 13.9 19.7 20.2 52.3 42.5 0.0 10.0 20.0 30.0 40.0 50.0 60.0 2011 2012 2013 2014 2015 9M'16 ($ MM) Capital Expenditures m ainly for Shandong Taibang ‘s new fractionation facility
Planned New Facility in Shandong 21 China Biologic Products, Inc. Expected Capital Expenditure In 2016 and 2017(RMB mm) Scheduled open time: Second half of 2017 Estimated Investment : RMB 800 - 1,000 million Fractionation capacity: expanding to a minimum of 1,200 tonnes from 700 tonnes 2016 2017 400 200 Shandong Taibang New Fractionation Facility
Improve collection volume at existing centers Establish more collection centers and enlarge collection territories Increase our stake in existing subsidiaries Further consolidate subscale players in the i ndustry Explore new products by internal R&D and external cooperation Improve yield of existing products Partner with major distributors in tier - one cities to dominate high end market Source raw material through strategic collaboration Organic Growth is O ur Strategic Focus and Priority Further develop direct sales model Develop marketing initiatives and execution Expand into complementary business through possible acquisition or partnership Future Growth Drivers 22 China Biologic Products, Inc. Increased Plasma Collection Ongoing Innovation Expand Sales Model Potential M&A
Superior Capability of Generating H igh Growth with Sustainable Profitability and Robust Cash Flow China Plasma Market in Early - Stage of Development with Significant Growth Potential High Entry Barrier Creating A Seller’s Market A Leading Player with Substantial Competitive Advantages 3 4 1 2 Why Invest in CBPO and the Highly Attractive Plasma Sector? 23 China Biologic Products, Inc.
$ MM 2011 2012 2013 2014 2015 9M’15 9M’16 Total sales 153.1 184.8 203.4 243.3 296.5 228.2 263.5 Cost of sales 46.0 58.8 65.5 80.1 106.5 79.5 93.2 Gross profit 107.1 126.0 137.9 163.2 190.0 148.7 170.3 Operating expenses Selling expenses 14.6 14.5 10.6 10.7 10.0 7.2 7.3 G&A expenses 31.5 34.0 36.2 32.1 41.4 27.5 39.0 R&D expenses 4.0 3.0 4.2 4.2 6.0 4.0 3.4 Income from operations (1) 32.2 74.5 86.9 111.2 132.6 110.0 120.6 Income before income taxes 42.3 81.1 92.4 122.8 135.1 111.6 126.4 Net income 31.4 66.0 76.9 96.1 114.1 93.8 105.6 Net income attributable to CBPO 18.2 45.2 54.6 70.9 89.0 72.8 85.3 1. Excluding some non - recurring items, such as impairment loss of goodwill and loss on abandonment and write - off of long - lived assets in 2011, and provision for other receivables in respect of an employee housing development project in 2014, the recurring operating income for relevant periods is as below. Refer to Appendix I for reconciliation of income from operations to recurring operating income $ MM 2011 2012 2013 2014 2015 9M’15 9M’16 Recurring operating income 57.0 74.5 86.9 116.2 132.6 110.0 120.6 2011 2012 2013 2014 2015 9M’16 Total Cash (2) ($ MM) 89.4 132.5 181.2 144.5 182.9 203.2 Cash & Cash Equivalents ($ MM) 89.4 129.6 144.1 80.8 144.9 203.2 Restricted Cash and Deposit ($ MM) - 2.9 30.5 63.7 - - Time Deposits ($ MM) - - 6.6 - 38.0 - Short - term and Long - term Bank Loans ($ MM) 11.0 7.9 39.8 97.9 - - Accounts Receivable Days 32 28 26 28 27 33 Inventory Days 490 456 458 433 390 464 2. Calculated as the sum of cash & cash equivalents and restricted cash Income Statement and Balance Sheet Highlights 24 China Biologic Products, Inc.
Appendix China Biologic Products, Inc.
Reconciliation of Non - GAAP Net income Attributable to Equity Holders Appendix I 26 $ MM, except EPS in $ and number of shares in MM 2011 2012 2013 2014 2015 9M’16 Net Income Attributable to Equity holders 18.2 45.2 54.6 70.9 89.0 85.3 Non - cash employee stock compensation 4.9 4.6 4.4 4.7 11.1 14.6 Impairment loss of goodwill 18.2 - - - - - Loss on abandonment of long - lived assets attributable to controlling interest 3.6 - - - - - Written - off of raw material attributable to controlling interest due to closure of plasma stations 0.1 - - - - - Interest on the Notes 3.6 - - - - - Gain (loss) from change in fair value of embedded conversion option in the Notes - 6.4 - - - - - Gain (loss) from change in fair value of warrants - 5.7 - 1.8 - - - - Adjusted Net Income Attributable to Equity holders - Non GAAP 36.5 48.0 59.0 75.6 100.1 99.9 Diluted EPS - Non GAAP 1.37 1.79 2.12 2.89 3.68 3.57 Weighted average number of shares used in computation of Non GAAP diluted EPS 26.7 26.8 27.6 25.7 26.6 27.2 China Biologic Products, Inc. $ MM, except percentage 2011 2012 2013 2014 2015 9M’16 Income from operations 32.2 74.5 86.9 111.2 132.6 120.6 Operating margin 21.0% 40.3% 42.7% 45.7% 44.7% 45.7% Excludes non - recurring items: Impairment loss of goodwill 18.2 - - - - - Loss on abandonment and write - off of long - lived assets 6.6 - - - - - Provision for other receivables in respect of an employee housing development project - - - 5.0 - - Recurring operating income 57.0 74.5 86.9 116.2 132.6 120.6 Recurring operating margin 37.2% 40.3% 42.7% 47.8% 44.7% 45.7% Reconciliation of Income from Operations to Recurring Operating Income
Appendix II - Plasma Donor Management 27 China Biologic Products’ Fuping Plasma Collection Center in Shaanxi Five steps to assure safe plasma from healthy donors II. Five times fingerprint identification III. ID card identification system I. Facial identification V. Fully - automatic plasma collection machine; fully enclosed and disposable medical instruments IV . Physical examination before donating plasma to assure up to standards for HBsAg, HCV , HIV, ALT, and syphilis China Biologic Products, Inc.
Disqualification Qualification Appendix II - Plasma Donor Management 28 Safety measures in every production phase Plasma checking by collection station Plasma rechecking by fractionator Another plasma donation by the same donor after 90 days Checking of re - donated plasma by fractionator Plasma collected on first day goes to production Destruction Qualification Qualification Disqualification plasma waiting period for 110 days at least First day of plasma donation Disqualification Reducing safety risks of plasma collection with a TRIPLE virus detection defense system 2 3 1 China Biologic Products, Inc.
KPMG China Biologic Products, Inc. Ming Yin, Senior Vice President 18th Floor , 19 Chaoyang Park Road Chaoyang District, Beijing 100127, PRC. China: +86 10 6598 3099 ir@chinabiologic.com IR Agent ICR LLC Bill Zima, Partner China: +86 10 6583 7511 U.S.: +1 646 405 5191 William.Zima@icrinc.com Legal counsel Davis Polk & Wardwell LLP Independent auditor For more information please visit us at : www.chinabiologic.com Contacts 29 China Biologic Products, Inc.
THANK YOU
+7X3S##I.K7P*YMK5:KZVZ4/\^V]D^>6'J0=I.*=K[O=NR5
M[6N_7R=G8_JEHK^5IO\ @I?^VME67XI:9L+!Q_Q;?X>D-&0$VJ?["S]X,RG&
MXMP2(P,RG_@IC^VA@X^*.EJP8#:_PY^'X! )!9BNA'"'^,C+!\",%"2/+JY7
M6HWYJV&:C>[A4D[6Z_ F[[I)-M=#)P:=M':VJN];M6T5[JVNEM5KJ?U045_*
MA=?\%-_VTXE4K\5M+&9""?\ A6WP\.-H!$;?\2$@2$G#X!4*048MFN#U3_@J
MO^W';&>*'XL:3'(NX1@_#/X<-*Q'S?=;P\T84+G!+9* G,WR5<+
M7IWDUS)2U7-%2LUNXNRO*2?5.-[;\S?R)_9 ,(V$E WS+Y\?S./E(1=G&?\
M6;N0,&(DMAJ3^RG+1GW[@ /EJYG6K"*&(S!!D(T2Y@<@
M1KA0S9;Y7085F/$1)C<%CD? 8C&RJ3FI7;E*-HK>5VD[V2246Y7LW=*[5[G-
M?F=W9MRE=I-V:7VF[ZI6C=VU:6YXEJCF%;E@'!1QE4B"-M4 D! Y$/?$BEC'
MG< >5/G6J%96D,4)<-&6:3RE"K'MP4,6[$K>9R
S341:ZRWO9)V3]Y;))V;7*FWT4FD^923]9-VS1@95BVY9(C"H15!'E;
M6WG)CY\I7R*1O&+$$,%5BH5HHHG\L*&WG:=
M_( /F&/.Y#F8L8SL'T>6YBHRO&2]YVMM[UDDY*Z:LFVULG97=V$)6EK9='OL
MNTE:/Q:Z-KW5JF[Q]?BNL[D*X 7;DPJYE,A#G;EANWX+'('G8WM@@+73Z;>,
MVS>F_P YPP98@WDJF-NUR09$8G'1?.(V,$ R?"++7))I8V27,3Y"MY3DH6;/
MW0V)5X)&TCS!B1<+P?3-'U%97+_(0BE8=T38E
:S;A>ZW27/3E)ZUG<7*[?
M,1Y'S\Q&\"4A2JX)/#JG0_S7*U\2MHW[CEHI7^S*Z
M32NU[KMKQDFCQ,/E8I*NQG8R.=YYWGM7 X*DF/K&"QQ6+>^'FD1U5G!$96
M! \A.\DL57=@9"Y?!^7:2P)?Y1Z-:P+)P!P!@HK]N=PVOG$9.UBWV)_P $4OV4_P!@;X[_ !Q^)'BW_@HO\>?A
ME\,/@S\'O!^CZWX>^&7CSXSZ-\'K_P#: \;>)+O6O+TW3+Y-:T+QGXD\,?#[
M0O#FIZIXJ\+?#6^L?%^M:]K_ ( L;:^?29==T;6OYOSO!4LLXAS7+L*Y*A@\
MUQV$P[K5'*I['"8J=&FJE1I*1)0AVDRJ(I(B.0[;<2F0X?"[6F($BD $5]&>
M-?"GB7P7K5YX8\5^'==\.>)8C;6\WA_6=-GT[5HWNW'V'&G7D"7
F /W9R^6KW?XO\ PN^+_@/PYX<\<>.OAIXX\$^$O&JP-X-\2^*/
M"^JZ/X?\6)?::-8LY/#VKWMI;V.LK>:0RZE"=.FF%Q8$7%N-GSGG/ W['7[7
M?QD\-P>-OA;^SE\9/&W@O4E,^E^+=)\(7D6A:U'#(\,TGAS5-2CL;/7[6*6&
M>"2ZT234;5+B&:RDE%[%)&OQE3#UZ55*49.,K1O%N7/%!/#WQ)\ 7WPP^+>M77A/Q)"UUI%QJ>A>'([W2;Z:WMY
M[>=Y;*Y)DMCYO[DLWG R%&'F5,LE4QWU+GCS3J^Q3:GR-R_NV'R(!.&:OJ*62*C3D^5+EO9M:+1ZM
MIN2MRO:^]HWOKJJ,H14;.*3BFTUKK*U]HJ+Y4WT2]W7F<9_+M] D D5 V_8
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M*N^\_(R\#@;3G;Q+P83@''XW+BJO+FA[?9RBXQT:4=&URMWE+D3EJDKQO?
,-C"G